Additional Study Information: Cisplatin is a chemotherapy medicine that is used to treat a variety of cancers. At high total (cumulative) doses it can be associated with progressive and irreversible hearing loss. The purpose of this study is see if injections of OTO-104 can protect against hearing loss associated with cisplatin therapy in the treatment of cancer. OTO-104 contains an active ingredient, called dexamethasone that has been shown to protect against hearing loss associated with cisplatin therapy. If you qualify to participate in this study, you will receive OTO-104 in the same ear before each of your first few cisplatin treatment cycles, for a maximum of 3 administrations. You could receive OTO-104 fewer than 3 times if you receive less than 3 cisplatin treatment cycles.